Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate.


Ten women with endometriosis were treated with medroxyprogesterone acetate (MPA), 150 mg intramuscularly every second week. After 2 weeks, there was a significant (8%) decrease in the high-density lipoprotein (HDL) concentration. This reduction became more pronounced after 8 and 24 weeks' medication. The HDL reduction was confined to the HDL2 subfraction, which was decreased by 15%, 33%, and 58% after 2, 8, and 24 weeks, respectively; there was no significant change in the HDL3 concentration. During treatment, there was a continuous increase in the mean MPA plasma level and a strong inverse correlation between this level and the mean HDL and HDL2 cholesterol concentrations. It was concluded that MPA affects HDL metabolism in a dose-dependent way and in the same direction as other progestins.


Citations per Year

2,090 Citations

Semantic Scholar estimates that this publication has 2,090 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Fhraeus1986LipoproteinCD, title={Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate.}, author={Lars F{\aa}hraeus and Adam Sydsj{\"{o} and Lars Wallentin}, journal={Fertility and sterility}, year={1986}, volume={45 4}, pages={503-6} }